Efficacy of Albumin-Bound Paclitaxel Combined with Nedaplatin in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma: A Single-Center Retrospective Observational Study

This single-center retrospective observational study assessed the efficacy and safety of albumin-bound paclitaxel combined with nedaplatin as neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC) in 41 patients. The study achieved a 100% R0 resection rate, with a 17.1% pathological complete response (pCR) rate and 51.2% of patients experiencing tumor downstaging. Common adverse events included hematologic toxicity (24.4%) and gastrointestinal reactions (17.1%), with no grade 4 or higher events. The results indicate that this combination therapy is effective and well-tolerated, offering a potential alternative to more toxic regimens, though the study's small sample size and lack of a control group are limitations.